Abbott Laboratories (ABT) : Fort Pitt Capital Group scooped up 504 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 249,928 shares of Abbott Laboratories which is valued at $11,234,264.Abbott Laboratories makes up approximately 1.33% of Fort Pitt Capital Group’s portfolio.
Other Hedge Funds, Including , Integrated Wealth Management reduced its stake in ABT by selling 1,277 shares or 3.75% in the most recent quarter. The Hedge Fund company now holds 32,791 shares of ABT which is valued at $1,473,955. Abbott Laboratories makes up approx 0.56% of Integrated Wealth Management’s portfolio.Signaturefd boosted its stake in ABT in the latest quarter, The investment management firm added 874 additional shares and now holds a total of 5,270 shares of Abbott Laboratories which is valued at $235,833. Abbott Laboratories makes up approx 0.03% of Signaturefd’s portfolio.Public Employees Retirement Association Of Colorado reduced its stake in ABT by selling 21,875 shares or 6.67% in the most recent quarter. The Hedge Fund company now holds 306,252 shares of ABT which is valued at $13,704,777. Abbott Laboratories makes up approx 0.11% of Public Employees Retirement Association Of Colorado’s portfolio.Wagner Bowman Management Corp reduced its stake in ABT by selling 173 shares or 1.08% in the most recent quarter. The Hedge Fund company now holds 15,878 shares of ABT which is valued at $693,392. Abbott Laboratories makes up approx 0.27% of Wagner Bowman Management Corp’s portfolio.First National Bank Of Omaha boosted its stake in ABT in the latest quarter, The investment management firm added 5,855 additional shares and now holds a total of 207,727 shares of Abbott Laboratories which is valued at $8,859,557. Abbott Laboratories makes up approx 0.67% of First National Bank Of Omaha’s portfolio.
Abbott Laboratories closed down -0.14 points or -0.31% at $44.81 with 65,83,457 shares getting traded on Thursday. Post opening the session at $45.06, the shares hit an intraday low of $44.78 and an intraday high of $45.09 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.